MREO Stockholder Alert: Robbins LLP Reminds Investors of the Class Action Lawsuit Against Mereo BioPharma Group plc

Core Viewpoint - A class action lawsuit has been filed against Mereo BioPharma Group plc, alleging that the company misled investors regarding the results of its Phase 3 studies for setrusumab, which did not meet primary endpoints, leading to significant stock price decline [1] Group 1: Allegations and Misleading Information - The lawsuit claims that Mereo BioPharma provided investors with overly optimistic statements about the Phase 3 ORBIT and COSMIC studies for setrusumab, suggesting confidence in its efficacy in reducing annualized fracture rates [1] - It is alleged that while making positive statements, Mereo concealed material adverse facts about the true state of the Phase 3 programs, which ultimately did not achieve their primary endpoints [1] Group 2: Impact on Stock Price - Following the announcement on December 29, 2025, that neither the ORBIT nor COSMIC studies met their primary endpoints, Mereo's American Depository Shares (ADS) plummeted from $2.31 to $0.29, representing a decline of over 87.7% [1]